Pieris Pharmaceuticals, Inc. (PIRS)
Stock Price:
$2.92 USD
0.03 (0.87%)
Updated December 3, 3:28 PM EST - Market open
Key Info
| Market Cap |
163.15M |
| Revenue (ttm) |
44.72M |
| Net Income (ttm) |
-26.43M |
| Shares Out |
54.34M |
| EPS (ttm) |
-0.49 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
December 3 |
| Last Price |
$2.92 |
| Previous Close |
$2.89 |
| Change ($) |
0.03 |
| Change (%) |
0.87% |
| Day's Open |
2.93 |
| Day's Range |
2.85 - 2.98 |
| Day's Volume |
208,163 |
| 52-Week Range |
1.61 - 4.24 |
More Stats
| Market Cap |
163.15M |
| Enterprise Value |
95.94M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
54.34M |
| Float |
n/a |
| EPS (basic) |
-0.48 |
| EPS (diluted) |
-0.49 |
| FCF / Share |
-0.92 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.02M |
| Short Ratio |
5.36 |
| Short % of Float |
n/a |
| Beta |
1.45 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
3.65 |
| PB Ratio |
3.78 |
| Revenue |
44.72M |
| Operating Income |
-22.84M |
| Net Income |
-26.43M |
| Free Cash Flow |
-49.78M |
| Net Cash |
67.21M |
| Net Cash / Share |
1.20 |
| Gross Margin |
103.50% |
| Operating Margin |
-51.08% |
| Profit Margin |
-59.10% |
| FCF Margin |
-111.32% |
| ROA |
-12.28% |
| ROE |
-73.37% |
| ROIC |
-37.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (5)
| Buy |
4 |
| Overweight |
1 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$7.67*
(163.12% upside)
Low
5.00
Current: $2.92
High
9.00
Target: 7.67
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | 46.28 | 29.10 | 25.28 | 5.83 | 2.93 | 5.37 | 12.43 |
| Revenue Growth | 59.03% | 15.14% | 333.46% | 98.88% | -45.35% | -56.83% | - |
| Gross Profit | 46.28 | 29.10 | 25.28 | 5.83 | 2.93 | 5.37 | 12.43 |
| Operating Income | -27.16 | -30.83 | -14.59 | -22.76 | -13.68 | -7.20 | 0.55 |
| Net Income | -25.47 | -26.75 | -17.65 | -22.80 | -14.06 | -9.85 | 0.07 |
| Shares Outstanding | 50.63 | 53.08 | 43.93 | 41.71 | 34.39 | 13.87 | 11.83 |
| Earnings Per Share | -0.56 | -0.50 | -0.40 | -0.55 | -0.41 | -0.71 | 0.01 |
| Operating Cash Flow | -52.47 | -1.07 | 49.75 | -14.39 | -12.71 | -5.07 | -3.08 |
| Capital Expenditures | -2.46 | -1.70 | -1.95 | -0.56 | -0.62 | -0.27 | -0.05 |
| Free Cash Flow | -54.93 | -2.76 | 47.80 | -14.95 | -13.33 | -5.33 | -3.13 |
| Cash & Equivalents | 104 | 128 | 72.63 | 29.36 | 29.35 | 18.47 | 3.76 |
| Total Debt | 15.48 | - | - | - | - | 1.27 | 4.75 |
| Net Cash / Debt | 88.67 | 128 | 72.63 | 29.36 | 29.35 | 17.20 | -0.99 |
| Assets | 141 | 141 | 104 | 35.06 | 33.95 | 21.86 | 7.28 |
| Liabilities | 89.75 | 101 | 92.35 | 9.84 | 2.82 | 3.85 | 6.69 |
| Book Value | 51.35 | 39.94 | 11.52 | 25.23 | 31.13 | 18.01 | 0.59 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Pieris Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
114 |
| CEO |
Stephen Yoder |
Stock Information
| Ticker Symbol |
PIRS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: PIRS |
Description
Pieris Pharmaceuticals, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Its lead respiratory program includes PRS-060, a drug candidate, which is in Phase I clinical trial that binds to IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immuno-oncology program comprises PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases. The company also develops PRS-344, a bispecific anticalin-antibody fusion protein that is in preclinical stage for oncology diseases; and PRS-080, a polyethylene glycol conjugated anticalin protein that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc.; and license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a research collaboration with the laboratories of University of Pittsburgh. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.